- Home
- SNT vs IFRX Comparison
SNT vs IFRX Comparison
Compare SNT & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNT
- IFRX
- Stock Information
- Founded
- SNT 1965
- IFRX 2007
- Country
- SNT Canada
- IFRX Germany
- Employees
- SNT N/A
- IFRX N/A
- Industry
- SNT Telecommunications Equipment
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- SNT Telecommunications
- IFRX Health Care
- Exchange
- SNT Nasdaq
- IFRX Nasdaq
- Market Cap
- SNT 74.4M
- IFRX 65.8M
- IPO Year
- SNT 1993
- IFRX 2017
- Fundamental
- Price
- SNT $3.35
- IFRX $1.58
- Analyst Decision
- SNT
- IFRX Strong Buy
- Analyst Count
- SNT 0
- IFRX 4
- Target Price
- SNT N/A
- IFRX $8.50
- AVG Volume (30 Days)
- SNT 14.3K
- IFRX 270.8K
- Earning Date
- SNT 06-12-2025
- IFRX 05-07-2025
- Dividend Yield
- SNT N/A
- IFRX N/A
- EPS Growth
- SNT N/A
- IFRX N/A
- EPS
- SNT 0.11
- IFRX N/A
- Revenue
- SNT $35,753,000.00
- IFRX $140,242.00
- Revenue This Year
- SNT N/A
- IFRX $106.72
- Revenue Next Year
- SNT N/A
- IFRX $66.89
- P/E Ratio
- SNT $29.95
- IFRX N/A
- Revenue Growth
- SNT 9.03
- IFRX 30.90
- 52 Week Low
- SNT $1.27
- IFRX $0.82
- 52 Week High
- SNT $3.97
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- SNT 51.14
- IFRX 58.67
- Support Level
- SNT $3.29
- IFRX $1.42
- Resistance Level
- SNT $3.55
- IFRX $1.68
- Average True Range (ATR)
- SNT 0.15
- IFRX 0.17
- MACD
- SNT 0.01
- IFRX 0.04
- Stochastic Oscillator
- SNT 56.34
- IFRX 64.37
About SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.